Seres Therapeutics (NASDAQ: MCRB) reported Q2 EPS of ($0.68), $0.05 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $4.6 million versus the consensus estimate of $6.57 million.

“Seres has made excellent progress across our deep pipeline of early and late, clinical and preclinical stage microbiome programs, and we were pleased to demonstrate the depth of our scientific leadership in this new therapeutic modality at our recent investor R&D event highlighting how we can change immunological tone using microbiome drugs.” said Roger J. Pomerantz, M.D., President, CEO and Chairman of Seres. “We continue to execute our SER-109 Phase 3 clinical study in patients with multiply-recurrent C. difficile infection. Following constructive meetings with the FDA, we are nearing initiation of a SER-287 Phase 2b clinical study in patients with active mild-to-moderate ulcerative colitis. Based on our FDA interactions, we expect the SER-287 Phase 2b study could be a pivotal trial that may serve as one of two required studies for product registration. We are also advancing work with our collaborators at MD Anderson Cancer Center and the Parker Institute for Immunotherapy to begin a Phase 1b study with SER-401 by year end to assess the potential for this microbiome therapy to augment clinical responses to checkpoint inhibitors in patients with metastatic melanoma.”

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.